Bosh sahifaBSLN • SWX
add
Basilea Pharmaceutica AG Allschwil
Yopilish kursi
41,15 CHF
Kunlik diapazon
40,60 CHF - 41,45 CHF
Yillik diapazon
32,00 CHF - 49,00 CHF
Bozor kapitalizatsiyasi
540,62 mln CHF
Oʻrtacha hajm
17,18 ming
Narx/foyda
47,10
Dividend daromadliligi
-
Asosiy maydon
SWX
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(CHF) | dek, 2023info | Y/Y qiyosi |
---|---|---|
Daromad | 36,36 mln | -19,30% |
Joriy xarajat | 7,96 mln | 12,34% |
Sof foyda | -10,69 mln | -187,82% |
Sof foyda marjasi | -29,41 | -208,81% |
Har bir ulushga tushum | — | — |
EBITDA | -7,88 mln | -152,08% |
Amaldagi soliq stavkasi | 0,08% | — |
Balans
Jami aktivlari
Jami passivlari
(CHF) | dek, 2023info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 59,93 mln | -29,21% |
Jami aktivlari | 173,29 mln | -21,53% |
Jami passivlari | 183,29 mln | -24,12% |
Umumiy kapital | -10,00 mln | — |
Tarqatilgan aksiyalar | 12,00 mln | — |
Narxi/balansdagi bahosi | -49,58 | — |
Aktivlardan daromad | -11,81% | — |
Kapitaldan daromad | -17,26% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(CHF) | dek, 2023info | Y/Y qiyosi |
---|---|---|
Sof foyda | -10,69 mln | -187,82% |
Operatsiyalardan naqd pul | -3,81 mln | -210,31% |
Sarmoyadan naqd pul | -322,50 ming | -100,69% |
Moliyadan naqd pul | -20,11 mln | -4,52% |
Naqd pulning sof oʻzgarishi | -24,31 mln | -178,80% |
Boʻsh pul | -4,62 mln | -154,24% |
Haqida
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
CEO
Tashkil etilgan
okt 2000
Sayt
Xodimlar soni
147